DexCom
DXCM
#913
Rank
A$39.59 B
Marketcap
A$102.62
Share price
3.47%
Change (1 day)
-18.89%
Change (1 year)

P/E ratio for DexCom (DXCM)

P/E ratio as of July 2026 (TTM): 29.7

According to DexCom's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 29.6875. At the end of 2025 the company had a P/E ratio of 30.9.

P/E ratio history for DexCom from 2006 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202530.9-41.65%
202452.9-39.89%
202388.0-31.61%
2022129-49.43%
2021254
2019201-341.22%
2018-83.2-14.47%
2017-97.327.09%
2016-76.5-31.78%
2015-112-38.86%
2014-183

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
30.1 1.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
26.4-10.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
23.2-21.94%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Becton Dickinson
BDX
29.0-2.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Edwards Lifesciences
EW
49.9 68.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Tandem Diabetes Care
TNDM
-4.99-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA
QuidelOrtho
QDEL
-1.10-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
West Pharmaceutical Services
WST
48.6 63.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.